Stevanato Group (NYSE:STVN) Given New $16.00 Price Target at UBS Group

Stevanato Group (NYSE:STVN) had its price target lowered by stock analysts at UBS Group from $23.00 to $16.00 in a report released on Wednesday, Benzinga reports. The firm currently has a “neutral” rating on the stock.

A number of other brokerages have also recently issued reports on STVN. Citigroup dropped their target price on shares of Stevanato Group from $26.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday. Weiss Ratings upgraded Stevanato Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, August 27th. William Blair downgraded Stevanato Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Stevanato Group in a research report on Wednesday, October 7th. They set a “hold” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy”.

Stevanato Group Stock Performance

NYSE STVN traded down €0.81 on Wednesday, hitting €13.29. 4,406,642 shares of the stock were exchanged, compared to its average volume of 535,738. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.61 and a quick ratio of 1.08. The business’s fifty day moving average is €20.35 and its 200 day moving average is €18.11. Stevanato Group has a 52 week low of €12.05 and a 52 week high of €27.00. The company has a market capitalization of $4.02 billion, a PE ratio of 23.72, a P/E/G ratio of 1.62 and a beta of 0.80.

Stevanato Group (NYSE:STVN) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported €0.16 EPS for the quarter, missing analysts’ consensus estimates of €0.17 by (€0.01). Stevanato Group had a net margin of 10.99% and a return on equity of 10.43%. The firm had revenue of €326.06 million during the quarter. Research analysts anticipate that Stevanato Group will post 0.69 EPS for the current fiscal year.

Insider Transactions at Stevanato Group

In other news, Director Luciano Santel sold 2,023 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of €20.09, for a total value of €40,642.07. Following the completion of the sale, the director owned 4,739 shares of the company’s stock, valued at approximately €95,206.51. The trade was a 29.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Marco Dal Lago sold 4,209 shares of the company’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of €20.09, for a total transaction of €84,558.81. Following the completion of the transaction, the chief financial officer owned 81,144 shares in the company, valued at €1,630,182.96. This trade represents a 4.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 21,926 shares of company stock valued at $459,738.

Institutional Investors Weigh In On Stevanato Group

Several institutional investors and hedge funds have recently bought and sold shares of STVN. Fifth Third Bancorp raised its position in Stevanato Group by 22.6% during the first quarter. Fifth Third Bancorp now owns 4,196 shares of the company’s stock valued at $58,000 after purchasing an additional 773 shares in the last quarter. Integrated Wealth Concepts LLC bought a new stake in Stevanato Group during the second quarter worth $59,000. State of Wyoming acquired a new stake in shares of Stevanato Group in the 3rd quarter valued at $75,000. Diversify Wealth Management LLC boosted its holdings in shares of Stevanato Group by 23.9% in the 1st quarter. Diversify Wealth Management LLC now owns 18,353 shares of the company’s stock valued at $252,000 after purchasing an additional 3,543 shares in the last quarter. Finally, First Bank & Trust increased its stake in shares of Stevanato Group by 3.4% in the 2nd quarter. First Bank & Trust now owns 18,417 shares of the company’s stock valued at $333,000 after purchasing an additional 603 shares during the last quarter.

Stevanato Group News Summary

Here are the key news stories impacting Stevanato Group this week:

• Positive Sentiment: Third-quarter revenue rose 8% year over year to €326.1 million. A valuation commentary also argued the shares could be undervalued following the results. Stevanato Group Q3 results Valuation commentary
• Neutral Sentiment: Several law firms announced investigations into whether Stevanato’s disclosures complied with securities laws. These are investigations, not findings of wrongdoing, and follow the company’s recent results and market reaction. Investigation announcement
• Negative Sentiment: Management said GLP-1-related revenue declined in Q3 and represented about 17%–18% of total revenue. The company expects only low-single-digit growth in 2027, citing lower GLP-1 syringe volumes tied to one customer—raising concerns about a key source of demand. 2027 outlook and GLP-1 volumes
• Negative Sentiment: Analysts reduced expectations: Citi cut its price target to $20 from $26 but kept a Buy rating; UBS lowered its target to $16 from $23 and maintained Neutral; William Blair downgraded the stock to Market Perform from Outperform. UBS target cut William Blair downgrade

Stevanato Group Company Profile

Stevanato Group S.p.A. is an Italy-based provider of drug-containment and drug-delivery solutions for the pharmaceutical, biotechnology and healthcare industries. Founded in 1949, the company has developed from a glass-packaging manufacturer into an integrated supplier serving customers throughout the global pharmaceutical supply chain.

The company manufactures primary packaging products, including glass vials, syringes, cartridges and ampoules, as well as components and systems used to contain and administer injectable medicines.